Doxil (Doxorubicin HCL liposome Injection) as Myeloma Treatment
Doxil as Chemotherapy for Multiple Myeloma
Doxil is a chemotherapy agent composed of Doxorubicin enclosed in liposomes (a type of fatty bubble that slowly releases the drug and helps reduce its toxicity). Doxil is approved for use in combination with Velcade to treat individuals with Multiple Myeloma who have previously received treatments other than Velcade.
How is Doxil (Doxorubicin) Given?
Doxil is given intravenously. When given in combination with Velcade, the recommended dose of Doxil is 30 mg/m2 administered over a one-hour infusion every three weeks on day four following Velcade. Individuals may be treated for up to eight cycles until disease progression or the occurrence of unacceptable side effects. Dose reductions in Doxil and or Velcade are made if an individual experiences certain side effects
What are the possible side effects of Doxil ?
Common side effects reported with Velcade-Doxil in a Phase III Clinical trial included gastrointestinal effects, peripheral neuropahty, asthenic conditions, fatigue, low blood counts, fever , rash , mouth sores, and pain associated with neuropathy. Serious side effects reported in > 5% individuals receiving the combination included neutropenia, thromobocytopenia, anemia, fatigues, asthenic conditions, diarrhea , peripheral neuropahty and hand-foot syndromes (HFS).
We will be posting more information about other treatments that are commonly used for managing Multiple Myeloma. You can use our Patient Navigator to find clinical trials for Multiple Myeloma.
The above information has been derived from a very useful, informative and simple to understand handbook created by the Multiple Myeloma Research Foundation (the MMRF) for patient and caregivers. I would highly recommend having a copy. I will see if we can request the MMRF to send us some free copies to send to our Cure Talk Readers.